Takeda Highlights Value Of Late-Stage Pipeline

At a recent R&D Day, Takeda shone a spotlight on its late-stage pipeline, which in its view has a combined peak revenue potential of $10-20bn across six assets, within which Phase III readouts for three are expected next year.

Oveporexton (TAK-861), a first-in-class oral orexin receptor 2 agonist for narcolepsy Type 1, the TYK2 inhibitor zasocitinib (TAK-279) for psoriasis, and the injectable hepcidin mimetic rusfertide (TAK-121; partnered with Protagonist...